An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease (HORIZON PLUS)

Medivation

Status and phase: Terminated; Phase 3

Conditions: Huntington Disease

Treatments: Drug: Dimebon (latrepirdine)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01085266

DIM20EXT

Details and patient eligibility

About

An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.

Enrollment: 362 patients

Sex: All

Ages: 30+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Successful completion of 26 weeks of blinded treatment in the HORIZON study

Exclusion criteria

• Any other medical illness or unstable medical condition that may interfere with their ability to comply with study procedures and abide by study restrictions, or may interfere with the ability to interpret safety information.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

362 participants in 1 patient group

Dimebon (latrepirdine)

Experimental group

Description:

Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.

Treatment:

Drug: Dimebon (latrepirdine)